日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.

定量 HER2 组织和血浆分析可预测曲妥珠单抗 deruxtecan 对乳腺癌的活性。

Tarantino Paolo, Kim Se-Eun, Hughes Melissa E, Kusmick Ross J, Smith Kalie, Brasó-Maristany Fara, Nyein Chan Nay Nwe, Paré Brunet Laia, Alder Laura, Garcia-Cortes Diana, Gomez Tejeda Zanudo Jorge, Pereslete Alyssa M, Noteware Laura, Moore Heather, Van Swearingen Amanda E D, Li Tianyu, Gupta Hersh, D'Amico Olivia, Martini Alba, Morganti Stefania, Spindel Jennifer, Cook Charmaine, McLaughlin Christine, Dvir Kathrin, Garrido-Castro Ana C, Sammons Sarah, Files Janet, Sendrick Kerry, Buck Simone, Dillon Deborah, Jeselsohn Rinath, Li Yvonne Y, Cherniack Andrew D, LoRusso Patricia, Lustberg Maryam, Vega-León Rosario, Pardo Francisco, Davis Justin, Mueller Claudius, Corgiat Brian, Curigliano Giuseppe, Anders Carey K, Petricoin Emanuel F, Rimm David L, Prat Aleix, Tayob Nabihah, Lin Nancy U, Tolaney Sara M

Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer

接受sacituzumab govitecan治疗的转移性乳腺癌患者的生存结果及DNADX ctDNA检测的作用

Morganti, S; Kusmick, R J; Hughes, M E; Brasó-Maristany, F; Smith, K; Tarantino, P; Vega-Leon, R; Grinda, T; Pardo, F; Dvir, K; Suggs, G L; Buck, S; Skeffington, M; Garrido-Castro, A C; Parsons, H A; Sammons, S L; Prat, A; Lin, N U; Tolaney, S M; Giordano, A

Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases

乳腺癌中枢神经系统转移患者接受sacituzumab govitecan治疗的真实世界结果

Grinda, Thomas; Morganti, Stefania; Hsu, Liangge; Yoo, Tae-Kyung; Kusmick, Ross J; Aizer, Ayal A; Giordano, Antonio; Leone, Jose P; Hughes, Melissa; Tolaney, Sara M; Lin, Nancy U; Sammons, Sarah L